Solifenacin: pharmacology and clinical efficacy.

about

Solifenacin: pharmacology and clinical efficacy.

Item

http://www.wikidata.org/entity/Q38177369

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Solifenacin: pharmacology and clinical efficacy.

@en

type

Item

label

Solifenacin: pharmacology and clinical efficacy.

@en

prefLabel

Solifenacin: pharmacology and clinical efficacy.

@en

P1476

Solifenacin: pharmacology and clinical efficacy.

@en

P2093

Dudley Robinson

http://www.w3.org/2001/XMLSchema#string

Linda Cardozo

http://www.w3.org/2001/XMLSchema#string

P2860

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder.

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study.

Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial.

Solifenacin demonstrates high absolute bioavailability in healthy men.

Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.

Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.

Pharmacokinetic effect of ketoconazole on solifenacin in healthy volunteers.

Pharmacokinetics, safety, and tolerability of solifenacin in patients with renal insufficiency.

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

P304

239-253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECP.09.3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233507965

http://www.w3.org/2001/XMLSchema#string

P698

24410703

http://www.w3.org/2001/XMLSchema#string